JP2004256522A - Composition for treating or preventing diabetes - Google Patents
Composition for treating or preventing diabetes Download PDFInfo
- Publication number
- JP2004256522A JP2004256522A JP2004026168A JP2004026168A JP2004256522A JP 2004256522 A JP2004256522 A JP 2004256522A JP 2004026168 A JP2004026168 A JP 2004026168A JP 2004026168 A JP2004026168 A JP 2004026168A JP 2004256522 A JP2004256522 A JP 2004256522A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- patent document
- diabetes
- evening primrose
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
本発明は、桑葉と、月見草を併用してなる、肥満及び糖尿病の予防・治療用組成物に関する。 The present invention relates to a composition for preventing and treating obesity and diabetes, comprising a combination of mulberry leaves and evening primrose.
肥満及び糖尿病は、過剰カロリーの摂取が主な原因となり、増加の一途をたどっている。糖尿病には、インスリン依存型糖尿病(I型糖尿病)とインスリン非依存型糖尿病(II型糖尿病)の2タイプがあるが、全体の90%は、後者のタイプである。インスリン非依存型糖尿病における高血糖の原因として、食後の急峻な血糖上昇に対応し、瞬時に分泌されるべきインスリン早期相の欠如と食後高血糖の持続により誘導される内因性基礎インスリン分泌低下が挙げられる。食後高血糖の是正は経口血糖降下剤、インスリンを用いても困難なことがあり、消化系における糖質の急速な吸収を防ぐ方法が有望である。消化系における糖質の吸収としては、第一段階として唾液中のα−アミラーゼ、第二段階として小腸中のα−グルコシダーゼが関与しており、これらの酵素を阻害することにより、食後の血糖値上昇が抑制され、さらにそれに続くインシュリン値の上昇も抑制されることが明らかにされている。 Obesity and diabetes are increasing due primarily to excess caloric intake. There are two types of diabetes, insulin-dependent diabetes (type I diabetes) and non-insulin-dependent diabetes (type II diabetes), of which 90% are of the latter type. The causes of hyperglycemia in non-insulin-dependent diabetes mellitus are the lack of an early phase of insulin that must be secreted instantaneously and the decrease in endogenous basal insulin secretion induced by the persistence of postprandial hyperglycemia in response to a sharp rise in blood glucose after meals. No. Correction of postprandial hyperglycemia can be difficult even with oral hypoglycemic agents and insulin, and methods to prevent rapid absorption of carbohydrates in the digestive system are promising. As the absorption of carbohydrates in the digestive system, α-amylase in saliva is involved in the first step, and α-glucosidase in the small intestine is involved in the second step. It has been shown that the rise is suppressed and the subsequent rise in insulin levels is also suppressed.
かかるアミラーゼ活性阻害物質としては、コムギ水抽出物(特許文献1)、ストレプトマイセス属微生物由来のT−76(特許文献2),N−61(特許文献3),X−2(特許文献4),I−1001(特許文献5),AI−B(特許文献6),アミロスタチンA(特許文献7),クラドスポリウム属微生物由来のトマスタチン(特許文献8),グラキスポリエラ属微生物の代謝産物(特許文献9)等が既に開示されている。 Examples of such an amylase activity inhibitor include wheat water extract (Patent Document 1), T-76 (Patent Document 2), N-61 (Patent Document 3), and X-2 (Patent Document 4) derived from microorganisms of the genus Streptomyces. ), I-1001 (Patent Document 5), AI-B (Patent Document 6), Amylostatin A (Patent Document 7), Tomasatin derived from Cladosporium sp. Patent Document 9) and the like have already been disclosed.
また、グルコシダーゼ活性阻害物質としては、エゾイシゲ抽出物(特許文献10),紅景天属植物(特許文献11),アカルボース、エミグリテート、ミグリトール及びボグリボース(特許文献12)等が既に開示されている。 Further, as the glucosidase activity inhibitor, Ezoishige extract (Patent Literature 10), Red-King Tengen plant (Patent Literature 11), acarbose, emiglitate, miglitol, voglibose (Patent Literature 12) and the like have already been disclosed.
しかしながら、これまでのアミラーゼ活性阻害物質やグルコシダーゼ活性阻害物質では、安定性,安全性,有効性の全てを満足するものは、未だ得られておいないのが実状である。 However, as a matter of fact, no amylase activity inhibitor or glucosidase activity inhibitor that satisfies all of stability, safety and efficacy has been obtained yet.
本発明で用いる桑葉は、クワ属(Morus L.)植物の乾燥葉からなる生薬であり、γ−アミノ酪酸(特許文献13)やアスコルビン酸(特許文献14)を含有し、HNE・アクロレインの生成抑制・分解促進作用(特許文献15),スクラーゼやマルターゼの活性阻害作用(特許文献16),チロシナーゼ活性阻害作用(特許文献17),グルコシダーゼ活性阻害作用(特許文献18),育毛作用(特許文献19)等が知られている。 The mulberry leaf used in the present invention is a crude drug consisting of dried leaves of a mulberry ( Morus L.) plant, contains γ-aminobutyric acid (Patent Document 13) and ascorbic acid (Patent Document 14), and contains HNE acrolein. Production inhibiting / degrading promoting action (Patent Document 15), sucrase and maltase activity inhibiting action (Patent Document 16), tyrosinase activity inhibiting action (Patent Document 17), glucosidase activity inhibiting action (Patent Document 18), hair growth action (Patent Document) 19) are known.
本発明で用いる月見草は、マツヨイグサ(Oenothera stricta Ledeb. ex Link),メマツヨイグサ(Oenothera biennis L.),オオマツヨイグサ(Oenothera erythrosepala Borb.)等のマツヨイグサ属植物(Oenothera L.)の総称である。月見草の有効性としては、抗酸化作用,抗アレルギー作用,フリーラジカル消去作用,美白作用(特許文献20),アポトーシス誘導作用(特許文献21)等が知られており、月見草油とl−メントールを併用した抗アレルギー剤(特許文献22)、乳発酵物と月見草を併用した健康食品(特許文献23)、ロイヤルゼリー抽出物,高麗人参抽出物と月見草を含有する皮膚外用剤(特許文献24)、タイム抽出物と月見草油を含有する抗アレルギー食品(特許文献25)、コウジ酸と月見草エキスを併用した皮膚外用剤(特許文献26)等も開示されている。 The evening primrose used in the present invention is a general term for Oenothera L. plants such as Oenothera stricta Ledeb. Ex Link, Oenothera biennis L., Oenothera erythrosepala Borb. As the effectiveness of evening primrose, antioxidant action, antiallergic action, free radical scavenging action, whitening action (Patent Document 20), apoptosis inducing action (Patent Document 21) and the like are known, and evening primrose oil and l-menthol are used. An antiallergic agent used in combination (Patent Document 22), a health food using milk fermented product and evening primrose in combination (Patent Document 23), a royal jelly extract, a skin external preparation containing ginseng extract and evening primrose (Patent Document 24), Antiallergic foods containing thyme extract and evening primrose oil (Patent Document 25), skin external preparations using a combination of kojic acid and evening primrose extract (Patent Document 26), and the like are also disclosed.
しかしながら、桑葉と月見草を併用して用いること、及びこれらの成分を併用することにより、肥満及び糖尿病を予防・治療する効果が相乗的に向上することは、これまで全く知られていなかった。 However, it has never been known that the combined use of mulberry leaves and evening primrose and the combined use of these components synergistically improve the effects of preventing and treating obesity and diabetes.
そこで本発明においては、肥満及び糖尿病を予防・治療する効果に優れ、しかも、安全性,安定性,有効性を満足させることのできる組成物を提供することを目的とした。 Accordingly, an object of the present invention is to provide a composition which is excellent in the effects of preventing and treating obesity and diabetes, and which can satisfy safety, stability and efficacy.
先に述べた課題を解決するべく種々検討したところ、本発明者らは、桑葉と、月見草を併用することにより、肥満及び糖尿病を予防・治療する効果に優れ、しかも、安全性,安定性,有効性を満足させることのできる組成物を提供することができることを見いだし、本発明を完成するに至った。 After conducting various studies to solve the above-mentioned problems, the present inventors have found that the combined use of mulberry leaves and evening primrose has an excellent effect of preventing and treating obesity and diabetes, and furthermore, is safe and stable. It has been found that a composition capable of satisfying the effectiveness can be provided, and the present invention has been completed.
月見草エキス及び桑葉エキスを併用することによるα−グルコシダーゼ及びα−アミラーゼの活性阻害作用について検討を行った。 The activity inhibitory effect of α-glucosidase and α-amylase by using together with evening primrose extract and mulberry leaf extract was examined.
試験検体
月見草エキスとしてはオリザ油化より市販されている月見草エキスを、桑葉エキストしては日本新薬より市販されている桑の葉エキスを、それぞれ0.1重量%濃度と成るようリン酸緩衝液(pH7.0)で希釈し,表1に示した比率で用いた。
Test specimens As a evening primrose extract, a night primrose extract commercially available from Oriza Yuka, and a mulberry leaf extract, a mulberry leaf extract commercially available from Nippon Shinyaku, were each phosphate buffered to a concentration of 0.1% by weight. The solution was diluted with a solution (pH 7.0) and used at the ratios shown in Table 1.
α−グルコシダーゼ活性阻害作用
市販ラット腸管アセトン粉末(SIGMA社製)に9倍量のリン酸緩衝液(pH7.0)を加え、氷中にてガラスホモジナイザーで均質化した後、遠心分離(3000rpm,10分,4℃)し、上清を粗酵素液とした。マルトースの分解には粗酵素液を20倍希釈、スクロースの分解には2倍希釈して用いた。
2%マルトースまたは2%スクロース溶液0.6mLに、エキスを表1に示した比率で混合したものを0.6mL添加し、37℃で5分間保温後、上記粗酵素液を0.6mL加え、37℃にて30分間反応させた。対照にはリン酸緩衝液を添加した。ブランクには失活酵素を用いた。反応停止は煮沸水中に10分間過熱して酵素を失活させた。反応停止後、遠心分離(3000rpm,10分間,4℃)し、その上清中のグルコース量をグルコースオキシダーゼ法にて定量した。発色試液3mLに対して上清を20μL入れ、37℃で20分間反応させた後、吸光光度計を用いて490nmの吸光度を測定し、グルコース量を求めた。
α-Glucosidase activity inhibitory action A 9-fold amount of phosphate buffer (pH 7.0) was added to commercially available rat intestinal acetone powder (manufactured by SIGMA), homogenized with a glass homogenizer in ice, and then centrifuged (3,000 rpm, (10 minutes, 4 ° C), and the supernatant was used as a crude enzyme solution. The crude enzyme solution was diluted 20-fold for maltose decomposition and 2-fold diluted for sucrose decomposition.
To 0.6 mL of a 2% maltose or 2% sucrose solution, 0.6 mL of a mixture obtained by mixing the extract at the ratio shown in Table 1 was added, and the mixture was kept at 37 ° C. for 5 minutes. Then, 0.6 mL of the above crude enzyme solution was added. The reaction was performed at 37 ° C. for 30 minutes. A phosphate buffer was added to the control. Inactivated enzyme was used as a blank. The reaction was stopped by heating in boiling water for 10 minutes to inactivate the enzyme. After stopping the reaction, the mixture was centrifuged (3000 rpm, 10 minutes, 4 ° C.), and the amount of glucose in the supernatant was quantified by the glucose oxidase method. After 20 μL of the supernatant was added to 3 mL of the color developing solution and reacted at 37 ° C. for 20 minutes, the absorbance at 490 nm was measured using an absorptiometer to determine the amount of glucose.
α−アミラーゼ活性阻害作用
ヒト唾液由来のα−アミラーゼ(SIGMA社製)を255unit/mLとなるように0.1Mリン酸緩衝液(pH7.0)で調製した。α−アミラーゼの活性を測定するためにヨードデンプン法を用いた。基質溶液1mLに、エキスを表1に示した比率で混合したものを1.0mL添加し、37℃で5分間保温後、α−アミラーゼ溶液を0.02mL(5.35unit)加え、37℃にて30分間反応させた。対照にはリン酸緩衝液を添加、ブランクには失活酵素を用いた。30分の反応後、発色溶液で反応をとめ、5mLの精製水を添加して吸光光度計を用いて660nmの吸光度を測定し、デンプン量を求めた。
α-Amylase activity inhibitory action α-amylase derived from human saliva (manufactured by SIGMA) was prepared in a 0.1 M phosphate buffer (pH 7.0) to a concentration of 255 units / mL. The iodo starch method was used to measure the activity of α-amylase. To 1 mL of the substrate solution, 1.0 mL of a mixture obtained by mixing the extract at the ratio shown in Table 1 was added, and the mixture was incubated at 37 ° C for 5 minutes, and then 0.02 mL (5.35 units) of the α-amylase solution was added. For 30 minutes. Phosphate buffer was added as a control, and inactivated enzyme was used as a blank. After the reaction for 30 minutes, the reaction was stopped with a coloring solution, 5 mL of purified water was added, and the absorbance at 660 nm was measured using an absorptiometer to determine the amount of starch.
表1に各酵素に対する阻害率を示したとおり、桑葉エキスと、月見草エキスを併用して用いることにより,それぞれ単独で使用するよりも低濃度で、各酵素に対する阻害効果を発揮することができた。 As shown in Table 1, the inhibitory rate for each enzyme is shown. By using the mulberry leaf extract and evening primrose extract together, the inhibitory effect on each enzyme can be exhibited at a lower concentration than when each is used alone. Was.
なお、桑葉エキスと月見草エキスを併用することによる毒性,刺激性,アレルゲンなどの発現は認められず,安全性上特に問題は認められなかった。 No toxicity, irritation, or allergen expression was observed when the mulberry leaf extract and evening primrose extract were used in combination, and no particular safety problems were observed.
上述のとおり、肥満及び糖尿病を予防・治療する効果に優れ、しかも、安全性,有効性を満足させることのできる組成物を提供することができた。 As described above, it was possible to provide a composition that is excellent in the effects of preventing and treating obesity and diabetes, and that can satisfy safety and efficacy.
本発明の実施の形態を説明する。 An embodiment of the present invention will be described.
本発明において桑葉は乾燥させた乾燥葉を用いる。桑葉はそのまま糖尿病予防・治療用組成物として用いることができ、またエタノールや水等の溶媒を用いて抽出して得られる抽出物を用いることもできる。本発明の糖尿病予防・治療効果の観点から、熱水を用いて抽出した抽出物を用いることが、最も好ましい。 In the present invention, dried mulberry leaves are used. Mulberry leaf can be used as it is as a composition for diabetes prevention / treatment, and an extract obtained by extraction with a solvent such as ethanol or water can also be used. From the viewpoint of the diabetes prevention / treatment effect of the present invention, it is most preferable to use an extract extracted using hot water.
本発明において、月見草は、種子から搾油した油分をそのまま、若しくは精製して用いることができる。また、種子を粉砕し、エタノールや水等の溶媒を用いて抽出して得られる抽出物を用いることもできる。本発明の糖尿病予防・治療効果の観点から、熱水若しくはエタノールを用いて抽出した抽出物を用いることが、好ましい。 In the present invention, evening primrose can be used as it is or after refining the oil squeezed from seeds. Further, an extract obtained by pulverizing seeds and extracting with a solvent such as ethanol or water can also be used. From the viewpoint of the diabetes prevention / treatment effect of the present invention, it is preferable to use an extract extracted using hot water or ethanol.
[実施例1] 散剤
(1)ケイ酸アルミン酸マグネシウム 95.1(重量%)
(2)カルボキシメチルセルロースカルシウム 4.5
(3)桑葉エキス 0.2
(4)月見草エキス 0.2
製法:(1)〜(4)の成分を混合後、粉砕機にて粉砕し、均一に分散する。
[Example 1] Powder
(1) Magnesium aluminate silicate 95.1 (% by weight)
(2) carboxymethylcellulose calcium 4.5
(3) Mulberry leaf extract 0.2
(4) Evening primrose extract 0.2
Production method: After mixing the components (1) to (4), the mixture is pulverized with a pulverizer and uniformly dispersed.
[実施例2] キャンデー
(1)白糖 60.0(重量%)
(2)水飴 39.0
(3)桑葉エキス 0.4
(4)月見草エキス 0.5
(5)香料 0.1
製法;(1)と(2)を加熱混合均一化した後冷却し、70℃で(3)〜(5)の成分を添加し、混合均一化した後成型する。
[Example 2] Candy
(1) White sugar 60.0 (% by weight)
(2) Sugar syrup 39.0
(3) Mulberry leaf extract 0.4
(4) Evening Primrose Extract 0.5
(5) Fragrance 0.1
Manufacturing method: (1) and (2) are mixed by heating, then cooled, the components (3) to (5) are added at 70 ° C., and the mixture is homogenized and molded.
[実施例3] 錠剤
桑葉エキス75g、月見草エキス75gを混合し、同量の乳糖及びステアリン酸マグネシウム5gと混合し、打錠機にて直径10mm、重量300mgの錠剤を製造した。
Example 3 Tablets 75 g of mulberry leaf extract and 75 g of evening primrose extract were mixed, mixed with the same amount of lactose and 5 g of magnesium stearate, and manufactured into tablets having a diameter of 10 mm and a weight of 300 mg by a tableting machine.
[実施例4] 健康茶
ウーロン茶の熱水抽出物100重量部に、桑葉エキス1重量部,月見草エキス1重量部,アスコルビン酸1重量部を添加して、健康茶とした。
Example 4 Healthy Tea A healthy tea was prepared by adding 1 part by weight of mulberry leaf extract, 1 part by weight of evening primrose extract, and 1 part by weight of ascorbic acid to 100 parts by weight of a hot water extract of oolong tea.
Claims (1)
A composition for preventing and treating obesity and diabetes, comprising a combination of mulberry leaves and evening primrose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004026168A JP2004256522A (en) | 2003-02-06 | 2004-02-03 | Composition for treating or preventing diabetes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003029056 | 2003-02-06 | ||
JP2004026168A JP2004256522A (en) | 2003-02-06 | 2004-02-03 | Composition for treating or preventing diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2004256522A true JP2004256522A (en) | 2004-09-16 |
Family
ID=33133704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004026168A Pending JP2004256522A (en) | 2003-02-06 | 2004-02-03 | Composition for treating or preventing diabetes |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2004256522A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006103895A1 (en) * | 2005-03-29 | 2006-10-05 | Hiromichi Yamashita | Appetite-suppressing agent and air-conditioning apparatus for dieting |
KR100962292B1 (en) | 2008-06-09 | 2010-06-11 | 주식회사 비아이지 | Pharmaceutical composition for preventing and treating diabetes comprising extract of Mulberry leaves-Phellinus linteus mycelia |
KR101533191B1 (en) * | 2014-04-18 | 2015-07-02 | 주식회사김정문알로에 | A pharmaceutical composition for the prevention and treatment of type 2 diabetes comprising fraction concentrated Aloe vera gel and Evening Primrose Seed Extract |
CN104857081A (en) * | 2015-05-22 | 2015-08-26 | 广州白云山星群(药业)股份有限公司 | Health-care composition assisting in blood glucose reduction as well as preparation method and application of health-care composition |
WO2021080297A1 (en) * | 2019-10-24 | 2021-04-29 | (주)닥터티제이 | Composition containing evening primrose flower extract as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby |
-
2004
- 2004-02-03 JP JP2004026168A patent/JP2004256522A/en active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006103895A1 (en) * | 2005-03-29 | 2006-10-05 | Hiromichi Yamashita | Appetite-suppressing agent and air-conditioning apparatus for dieting |
KR100808565B1 (en) * | 2005-03-29 | 2008-02-29 | 히로미치 야마시타 | Anorectic agent and air regulator for diet |
KR100962292B1 (en) | 2008-06-09 | 2010-06-11 | 주식회사 비아이지 | Pharmaceutical composition for preventing and treating diabetes comprising extract of Mulberry leaves-Phellinus linteus mycelia |
KR101533191B1 (en) * | 2014-04-18 | 2015-07-02 | 주식회사김정문알로에 | A pharmaceutical composition for the prevention and treatment of type 2 diabetes comprising fraction concentrated Aloe vera gel and Evening Primrose Seed Extract |
CN104857081A (en) * | 2015-05-22 | 2015-08-26 | 广州白云山星群(药业)股份有限公司 | Health-care composition assisting in blood glucose reduction as well as preparation method and application of health-care composition |
CN104857081B (en) * | 2015-05-22 | 2018-03-16 | 广州白云山星群(药业)股份有限公司 | Auxiliary hyperglycemic health composition and its preparation method and application |
WO2021080297A1 (en) * | 2019-10-24 | 2021-04-29 | (주)닥터티제이 | Composition containing evening primrose flower extract as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mahmood | A review of α-amylase inhibitors on weight loss and glycemic control in pathological state such as obesity and diabetes | |
EP0815857B1 (en) | Antiobestic agent containing procyanidin as the active ingredient | |
US6932990B2 (en) | Carbohydrate absorption inhibitor and method for manufacturing the same | |
JP4669920B2 (en) | Functional material that suppresses blood glucose rise and blood pressure rise | |
US20180104299A1 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity | |
JPH09291039A (en) | Antiobestic medicine comprising procyanidin as active ingredient | |
JP2009013123A (en) | Health-retaining preparation | |
KR102132066B1 (en) | Antioxidant and anti-Obesity composition comprising Psyllium Husk and Kaempferia parviflora, formulatiom using the composition and preparing method thereof | |
WO2015170881A1 (en) | Blood circulation improving or capillary activity increasing health functional food composition | |
JP2002293736A (en) | Maillard reaction inhibitor and composition containing the same | |
WO2017159679A1 (en) | Polysaccharide digestion inhibitor | |
KR20040041026A (en) | Nutritional Supplement Containing Alpha-glucosidase and Alpha-amylase Inhibitors | |
KR100549089B1 (en) | A Health Care Composition for treating or preventing intestinal disease and constipation | |
JP2009247254A (en) | Health drink | |
KR20130097537A (en) | Composition comprising mixture of hot water extract of curcuma longa radix, acorus gramineus soland and polygala tenuifolia to enhance cognition and memory | |
JP2004256522A (en) | Composition for treating or preventing diabetes | |
KR20120043426A (en) | Functional composition and health food using the same | |
JPWO2005094858A1 (en) | Antidiabetic composition | |
JP2004035510A (en) | Composition for prophylaxis or treatment of diabetes mellitus or its complication | |
JP2014239699A (en) | Blood adiponectin amount increasing agent | |
KR100654903B1 (en) | Composition for anti-inflammatory activity and regenerative effect of cartilaginous tissue | |
JP2005306801A (en) | ROSA RUGOSA THUNB.-DERIVED alpha-AMYLASE INHIBITOR, alpha-GLUCOSIDASE INHIBITOR, GLUCOSE ABSORPTION INHIBITOR AND THEIR USE | |
KR101935861B1 (en) | Functional food composition for removing hangover and improving liver function and manufacturing method for thereof | |
JP2004043354A (en) | Hyaluronidase inhibitor | |
JP2010043036A (en) | Saccharometabolism promoter |